STOCK TITAN

Vanguard reports zero beneficial holdings in Gossamer Bio (NASDAQ: GOSS)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Gossamer Bio Inc Schedule 13G/A (Amendment No. 6) reports that The Vanguard Group holds 0 shares of Common Stock and beneficial ownership of 0% of the class as disclosed. The filing explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or divisions to report holdings separately.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

Does Vanguard own any GOSS shares according to this Schedule 13G/A?

No, The Vanguard Group reports 0 shares and 0% beneficial ownership. The filing states Vanguard's internal realignment led subsidiaries or divisions to report holdings separately beginning January 12, 2026, and the filing is signed on 03/27/2026.

What does Amendment No. 6 to the Schedule 13G/A for GOSS indicate?

It amends prior disclosure to show no beneficial ownership by The Vanguard Group. The amendment notes an internal realignment and reliance on SEC Release No. 34-39538 for disaggregated reporting by Vanguard entities.

Who signed the Schedule 13G/A amendment for Gossamer Bio (GOSS)?

The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026. The signature certifies the reporting of 0 shares and the explanatory realignment language in the filing.

Does this filing indicate Vanguard manages GOSS shares for other clients?

The filing explains Vanguard and its managed accounts may have rights to dividends or proceeds in some circumstances. It states no other person's interest exceeds 5% and Vanguard entities report separately after the January 12, 2026 realignment.
Gossamer Bio

NASDAQ:GOSS

View GOSS Stock Overview

GOSS Rankings

GOSS Latest News

GOSS Latest SEC Filings

GOSS Stock Data

87.96M
218.57M
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO